Heterogeneity in the progression of idiopathic pulmonary fibrosis (IPF) might reflect diversity in underlying pathobiology, and represents a major challenge in the prediction of clinical progression and treatment benefit. Previous studies have found peripheral blood concentrations of several protein biomarkers to be prognostic for overall survival duration in patients with IPF, but these findings have generally not been directly compared and replicated between cohorts. We aimed to use the pivotal trials for pirfenidone to evaluate prognostic and predictive properties of biomarkers across multiple endpoints, and whether they are modulated by pirfenidone treatment.

中文翻译：

---

吡非尼酮治疗的特发性肺纤维化患者的预后和预测性生物标志物：能力和ASCEND试验的事后评估。

特发性肺纤维化（IPF）进展中的异质性可能反映了基础病理生物学的多样性，并且在预测临床进展和治疗获益方面构成了重大挑战。先前的研究发现，几种蛋白生物标志物的外周血浓度可预示IPF患者的总生存期，但这些发现通常并未直接进行比较和在人群之间重复。我们旨在利用对吡非尼酮的关键试验来评估生物标志物在多个终点的预后和预测特性，以及它们是否受到吡非尼酮治疗的调节。